


## Terazosin hydrochloride

Cat. No.:	HY-B0371F
CAS No.:	63074-08-8
Molecular Formula:	C <sub>19</sub> H <sub>26</sub> ClN <sub>5</sub> O <sub>4</sub>
Molecular Weight:	423.89
Target:	Adrenergic Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 16.67 mg/mL (39.33 mM; ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.3591 mL	11.7955 mL	23.5910 mL
	5 mM	0.4718 mL	2.3591 mL	4.7182 mL
	10 mM	0.2359 mL	1.1796 mL	2.3591 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active  $\alpha$ 1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment<sup>[1][2][3]</sup>.

#### IC<sub>50</sub> & Target

$\alpha$ 1-adrenoceptor<sup>[1]</sup>

#### In Vitro

Terazosin does not discriminate cloned  $\alpha$ 1-adrenoceptor subtypes transiently expressed in COS cells<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Terazosin can be used to promote stone discharge in treatment of ureteral stones. Terazosin is reportedly safe and effective in treatment of distal ureteral stones, especially stones >5 mm<sup>[3]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### CUSTOMER VALIDATION

- Neurochem Int. 2020 Dec 16;104942.
- Research Square Preprint. 2022 Jul.
- Authorea. March 31, 2022.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

---

## REFERENCES

- [1]. Michel MC, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8.
- [2]. Vincent J, et al. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90(5):1763-8.
- [3]. Ju M, et al. Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy. J Int Med Res. 2020 Apr;48(4):300060520904851.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA